Regenicin, Inc. (WDSTD.OB) Secures Licensing for Revolutionary New Skin Replacement Technology
Regenicin, even though still in the development stage, is already a promising biotech pioneer in next-gen skin substitutes via tissue engineering workflows. In fact, today the company reported the acquisition of a worldwide license to a proprietary technology which constitutes the aforementioned workflows. The technology, formerly controlled by Lonza Walkersville, a subsidiary of Lonza Group Ltd., will pass to Regenicin with the payment of an initial $3.25M obligation, as required by the licensing agreement, and can be deployed to treat burns, chronic wounds and a host of other plastic surgery operations where skin remediation is essential. CEO of WDSTD, Randall…